FRIDAY, Dec. 13, 2024 (HealthDay News) -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is ...

A new study published in the New England Journal of Medicine examines whether removing lymph nodes is always necessary in early breast cancer.

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

A “watch-and-wait” strategy might be the best option for some women with early-stage, low-risk breast cancer.According ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

Tissue Penetration: Consistent with the recently updated trial protocol, tissue Css levels were evaluated in addition to plasma Css levels. The 80 mg/day dose, in both treatment arms, achieved tissue ...

New Delhi: In a major push for the in situ redevelopment of slum and JJ clusters, Delhi Development Authority on Thursday approved an overhaul of the existing policy. During a meeting chaired by ...

Telix is working on the study with Hong Kong-based Grand Pharmaceutical Group which has dosed the first patient in China. Credit: Shutterstock / Komsan Loonprom Australian biotechnology company, Telix ...